2257-85-4Relevant academic research and scientific papers
On the photophysical properties of new luminol derivatives and their synthetic phthalimide precursors
Perez-Ruiz, Raul,Fichtler, Robert,Diaz Miara, Yrene,Nicoul, Matthieu,Schaniel, Dominik,Neumann, Helfried,Beller, Matthias,Blunk, Dirk,Griesbeck, Axel G.,Jacobi Von Wangelin, Axel
, p. 657 - 664 (2010)
The photophysical properties of a series of structurally related 4-aminophthalimides and the corresponding 5-aminophthalic hydrazides (luminols) are reported. Absorption, steady-state, and time-resolved fluorescence spectra of luminols exhibited substitution, solvent, and pH dependence. Singlet lifetimes have been determined by time-resolved laser flash spectroscopy. UV spectra in gas phase and DMSO solution were calculated by TD-DFT which revealed the existence of two low-energy excited singlet states with strong pH-sensitivity. Springer Science+Business Media, LLC 2010.
Pyridyl Radical Cation for C?H Amination of Arenes
R?ssler, Simon L.,Jelier, Benson J.,Tripet, Pascal F.,Shemet, Andrej,Jeschke, Gunnar,Togni, Antonio,Carreira, Erick M.
supporting information, p. 526 - 531 (2019/01/04)
Electron-transfer photocatalysis provides access to the elusive and unprecedented N-pyridyl radical cation from selected N-substituted pyridinium reagents. The resulting C(sp2)?H functionalization of (hetero)arenes furnishes versatile intermediates for the development of valuable aminated aryl scaffolds. Mechanistic studies that include the first spectroscopic evidence of a spin-trapped N-pyridyl radical adduct implicate SET-triggered, pseudo-mesolytic cleavage of the N?X pyridinium reagents mediated by visible light.
Scaffold Hopping and Optimization of Maleimide Based Porcupine Inhibitors
Ho, Soo Yei,Alam, Jenefer,Jeyaraj, Duraiswamy Athisayamani,Wang, Weiling,Lin, Grace Ruiting,Ang, Shi Hua,Tan, Eldwin Sum Wai,Lee, May Ann,Ke, Zhiyuan,Madan, Babita,Virshup, David M.,Ding, Li Jun,Manoharan, Vithya,Chew, Yun Shan,Low, Choon Bing,Pendharkar, Vishal,Sangthongpitag, Kanda,Hill, Jeffrey,Keller, Thomas H.,Poulsen, Anders
, p. 6678 - 6692 (2017/08/18)
Porcupine is an O-acyltransferase that regulates Wnt secretion. Inhibiting porcupine may block the Wnt pathway which is often dysregulated in various cancers. Consequently porcupine inhibitors are thought to be promising oncology therapeutics. A high throughput screen against porcupine revealed several potent hits that were confirmed to be Wnt pathway inhibitors in secondary assays. We developed a pharmacophore model and used the putative bioactive conformation of a xanthine inhibitor for scaffold hopping. The resulting maleimide scaffold was optimized to subnanomolar potency while retaining good physical druglike properties. A preclinical development candidate was selected for which extensive in vitro and in vivo profiling is reported.
3-AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS
-
Page/Page column 48, (2009/08/16)
The present invention relates to 3-azabicyclo[3.1.0]hexane derivatives, which are useful as vanilloid receptor (VR) ligands, methods of treating diseases, conditions and/or disorders modulated by vanilloid receptors with them, and processes for preparing them.
A new efficient synthesis of substituted luminols using multicomponent reactions
Neumann, Helfried,Klaus, Stefan,Klawonn, Markus,Strübing, Dirk,Hübner, Sandra,G?rdes, Dirk,Von Wangelin, Axel Jacobi,Lalk, Michael,Beller, Matthias
, p. 431 - 438 (2007/10/03)
A new general synthesis of substituted luminols (5-amino-2,3- dihydrophthalazine-1,4-diones) is presented. Diversely substituted luminol derivatives can be synthesized in three steps. The products are of interest as new materials, which exhibit chemiluminescence.
NOVEL QUINOXALINEDIONE DERIVATIVES, THEIR PREPARATION AND USE
-
, (2008/06/13)
A compound having the formula or a pharmaceutically acceptable salt thereof wherein R is hydrogen or hydroxy; R1 is hydrogen, alkyl, arylalkyl, (CH2)nOH, or (CH2) NR7R8; R5 and R6 are each independently hydrogen, halogen, NO2, CN, CF3, SO2NR7R8, PO3R9R10, alkyl, alkenyl, alkynyl, (CH2)nCONR7R8, (CH2)nCO2R10, NHCOR11, wherein R7 and R8 are each independently hydrogen or alkyl or together R7 and R8 form a ring of from three to seven atoms, R9 is hydrogen or alkyl, R10 is hydrogen or alkyl, R11 is hydrogen or alkyl, and n is an integer of from zero to four; A is a ring of five to seven atoms fused with the benzo ring at the positions marked a and b, and formed by the following bivalent radicals: a-NR12—CHR13—CHR14-b, a-CHR13—CHR14—NR12-b, a-CHR13—NR12—CHR14-b, a-CHR14—CH2—NR12—CHR13-b, a-CHR13—NR12—CH2—CHR14-b, a-CH2—CH2—CHR13—NR12-b, a-NR12—CHR12—CHR13—CH2—CH2-b, a-CH2—CH2—NR12—CH2—CH2-b, a-CH2—CH2—CH2NR12—CH2-b, a-CH2—NR12—CH2—CH2-b a-CH2—CH2—CH2—CH2—NR12-b, a-NR12—CH2—CH2—CH2—CH2-b, wherein R12 is hydrogen, CH2CH2OH, or alkyl, and R13 and R14 are each independently hydrogen, CN, CONH2, CH2NH2, CH2OH, alkyl, arylalkyl, alkenyl, or CO2R15, wherein R15 is hydrogen or alkyl. The compounds are useful in the treatment of disorders of mammals, responsive to the blockade of glutamic and aspartic acid receptors. Processes for preparing the compounds and novel intermediate useful in the processes are also included.
